⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of embecta and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
embecta
↗Parsippany, New Jersey, USA
embecta is a global medical device company singularly focused on diabetes care. Spun off from Becton, Dickinson and Company (BD) in 2022, the company leverages a 100-year legacy in insulin delivery to provide pen needles, insulin syringes, and injection-site accessories to over 30 million people in more than 100 countries.
Beyond its core consumables business, embecta is expanding into advanced insulin-delivery systems, including the development of a disposable patch pump for both type 1 and type 2 diabetes. The company operates globally with a focus on improving patient outcomes through innovative technology, educational resources, and strategic partnerships with pharmaceutical companies, particularly in the GLP-1 space.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$1B+
Founded:2022
Ownership:public
Status:operating
STOCK
Exchange:NASDAQ
Ticker:EMBC
Market Cap:$0.19B
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (Medical Device focused)
Modalities:Insulin Delivery Devices, Medical Consumables
Active Trials:0
Trial Phases:-
FDA Approvals:1
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Multiple pharmaceutical partners for GLP-1 drug delivery integration
COMPETITION
Position:Leader
Competitors:Becton, Dickinson and Company (BD), Novo Nordisk, Eli Lilly, Medtronic, Insulet
LEADERSHIP
Key Executives:
Devdatt (Dev) Kurdikar - CEO
LINKS
Website:embecta.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with embecta. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.